Sugi Predict

Sugi Predict / Compounds / SCHEMBL3205146

SCHEMBL3205146

SCHEMBL3205146

Cc1ccccc1NCCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 2/20 0.66
▸ ITGAV P06756 2/20 0.66
▸ MAPT P10636 3/20 0.64
▸ HTT P42858 1/20 0.64
▸ HPGD P15428 6/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ POLB P06746 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ NSD2 O96028 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.53
▸ AKR1C3 P42330 1/20 0.53
▸ AKR1C2 P52895 1/20 0.53
▸ AKR1C1 Q04828 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ ITGB1 P05556 2/20 0.51
▸ ITGA5 P08648 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31139405 1.00 ITGB3 (0.66) ITGB3ITGAVMAPTHTTHPGD
Hydrochloric Acid SCHEMBL10912163 0.98 ITGB3 (0.64) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL13948424 0.89 MAPT (0.60) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL9951704 0.87 ITGB3 (0.59) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL28225592 0.86 MAPT (0.56) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL11558469 0.85 MAPT (0.64) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL9926528 0.84 MAPT (0.62) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL19240434 0.83 ALDH1A1 (0.53) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL23189083 0.82 MAPT (0.60) ITGB3ITGAVMAPTHTTHPGD
SCHEMBL13948837 0.82 MAPT (0.60) ITGB3ITGAVMAPTHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-10-24 — — US disclosed
EP-4419529-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2024-08-28 — — EP disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 — — WO disclosed
CN-109503478-B 2, 3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivative and preparation method and application thereof 岭南师范学院 2020-04-24 — — CN disclosed
CN-109503478-A 2,3- dihydro -1H- quinolin-4-one thiosemicarbazone derivative and its preparation method and application 岭南师范学院 2019-03-22 — — CN disclosed
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 — — US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 — — US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 — — US disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 — — US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 — — US disclosed
EP-1885695-B1 INDOLINE COMPOUNDS FOURNIER LAB SA (FR) 2009-02-25 — — EP disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 — — US disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 — — US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 — — EP disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 — — US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 — — US disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 — — EP disclosed
WO-2007000550-A2 NOVEL INDOLINE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-01-04 — — WO disclosed
US-4593101-A Process for the preparation of 4-quinolinones RHONE-POULENC SANTE (FR) 1986-06-03 — — US disclosed
US-4585867-A Process for the preparation of 4-quinolinones RHONE-POULENC SANTE (FR) 1986-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 ITGB3 3711/4885ITGAV 3813/4885MAPT 2499/4885
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 ITGB3 4801/4885ITGAV 4857/4885MAPT 763/4885
US-20240352021-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB3 ITGB3 614/4885ITGAV 1847/4885MAPT 3537/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 ITGB3 4773/4885ITGAV 4824/4885MAPT 2324/4885
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 ITGB3 4368/4885ITGAV 4562/4885MAPT 582/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 ITGB3 3891/4885ITGAV 4126/4885MAPT 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.